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Fig 1. Hidradenitis suppurativa. Facial nodular acne and
inflammatory subcutaneous nodules on the axillae
appeared in the setting of renal transplantation while the
patient was on cyclosporine.
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To the Editor: Hidradenitis suppurativa (HS) is a
chronic, recurrent inflammatory dermatosis involving
apocrine glandbearing skin, whose management
has no formal guidelines.1Open access under CC BY-NC-ND license.In November 2010, a 23-year-old Indian man
consulted for severe facial acne associated with
suppurating lesions of major body folds, which
had started 2 years after he underwent kidney
transplantation in 2007 for renal failure of unknown
origin. His immunosuppressive treatment included
cyclosporine (Cs) 150 mg/day and mycophenolate
mofetil 1.5 g/day. Treatment with isotretinoin
(20 mg/day) was introduced in April 2010 but led
to worsening of facial nodular acne. Subsequently,
inflammatory subcutaneous nodules developed on
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crops. Besides these nodules, physical examination
revealed bridged scars, but no interconnecting
tracts. Histologic examination of a skin biopsy and
cultures ruled out Crohn disease and an opportu-
nistic infection, respectively. The diagnosis was
HS grade II according to the Hurley classification. A
6-month course of oxacillin (2 g/day), followed by a
combination of rifampicin (600 mg/day) with
clindamycin (600 mg/day) for 9 months were
ineffective (Fig 1). In February 2012, Cs was
replaced with tacrolimus (2 mg/day) based on
the hypothesis of a deleterious effect of Cs on
pilosebaceous apparatus and of a potential efficacy
of tacrolimus as suggested in another report.2
In November 2012, all inflammatory lesions had
disappeared (Fig 2).
To our knowledge, this patient is the first case of
HS appearing in the setting of organ transplantation.
Although a fortuitous association cannot be
excluded, considering the patient’s age, the clinical
scenario speaks in favor of an iatrogenic origin of HS.
Indeed, rare cases of iatrogenic HS have been
reported.3 Even if several Cs-responsive cases of
HS exist,4 Cs is known to induce hyperplasia of the
pilosebaceous apparatus.5 Isotretinoin may also
have played an aggravating role. This patient is
similar to one suffering from HS for more than
20 years, in whom treatment with Cs had been
ineffective.2 He was cured at the age of 40 years,
a few months after kidney transplantation, while
receiving tacrolimus and mycophenolate mofetil
as immunosuppressive treatment. We recently
observed another case of HS that appeared within
2 years after transplantation, for which we suggested
a switch from Cs to tacrolimus. Although tacrolimus
and Cs exert very similar immunosuppressive effects,
the former proved more effective than the latter
against HS in these cases. This may be due to the
fact that tacrolimus exerts fewer effects on the
pilosebaceous apparatus.
This observation suggests that patients in whom
HS develops while on Cs should be switched to
tacrolimus.
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Ipilimumab-associated Sweet syndrome in a
melanoma patient
To the Editor: We read with interest the recently
published letter ‘‘Ipilimumab-associated Sweet syn-
drome in a patient with high-risk melanoma,’’1 in that
we had a patient with a very similar presentation. A
57-year-old man with stage IIIC (T4b, N3, cM0)
melanoma was enrolled in a phase 3 randomized
study of adjuvant ipilimumab. Eleven days after his
first infusion of ipilimumab, he presented to his
oncologist with an itchy rash. He was on no other
new medications and denied fever, diarrhea,
myalgias, or other systemic symptoms.
The patient subsequently presented to the
dermatology service 6 weeks after his first dose of
ipilimumab with widespread erythematous, edema-
tous papules and plaques, some with pseudovesic-
ular appearance, and scattered pustules on the face,
trunk, arms, and dorsal hands (Fig 1). At the time of
evaluation, there was no evidence of melanoma
progression. Complete blood count was within
normal limits without peripheral neutrophilia. Skin
biopsies were performed and demonstrated promi-
nent papillary dermal edema with extensive neutro-
philic infiltrate extending to the subcutaneous tissue
with scattered eosinophils and plasma cells (Fig 2).
The histopathologic features were consistent with
Sweet syndrome (SS). The patient was treated with
oral prednisone, initial dose of 60 mg daily, with
rapid improvement. Prednisone was subsequently
